Thiazolopyridine

1. A compound of formula I

wherein,

R 1 is selected from morpholin-4-yl, phenyl and tetrahydropyran-4-yl;

R 2 is selected from

—(CH 2 ) n -aryl;

—(CH 2 ) n -aryl substituted by one or more substituents selected from the group consisting of halogen, lower alkoxy, lower alkyl, —(CH 2 ) n NR′R″, —O(CH 2 ) n —O-lower alkyl, and —(CH 2 ) n -heterocyclyl;

heteroaryl;

heteroaryl substituted by one or more substituents, selected from the group consisting of lower alkyl, lower alkoxy, —(CH 2 ) n NR′R″, —(CH 2 ) n -heterocyclyl, and —(CH 2 ) n -heterocyclyl substituted by one or more substituents selected from hydroxy, lower alkoxy, —(CH 2 ) n —OH, —(CH 2 ) n —O-lower alkyl and lower alkyl;

—(CH 2 ) n -cycloalkyl;

—(CH 2 ) n —O-lower alkyl;

NR′R″;

benzo[1,3]dioxole;

2-methyl-1-oxo-2,8-diaza-spiro[4,5]decane;

2-oxa-5-aza-bicyclo [2.2.1]heptane; or

1-oxa-8-aza-spiro[4.5]decane;

R′ and R″ are independently from each other selected from lower alkyl, —(CH 2 ) n -O-lower alkyl, cycloalkyl, and cycloalkyl substituted by hydroxy; and

n is 0, 1 or 2;

or a pharmaceutically acceptable salt thereof.

2. The compound of formula I in accordance with claim 1 , wherein R 1 is morpholinyl and R 2 is selected from phenyl, and phenyl substituted by a group selected from halogen, lower alkoxy and morpholinyl.

3. The compound of formula I in accordance with claim 2 , wherein the compound is selected from

4-fluoro-N-(7-methoxy-4-morpholin-4-yl-thiazolo[5,4-c]pyridin-2-yl)-benzamide,

N-(7-methoxy-4-morpholin-4-yl-thiazolo[5,4-c]pyridin-2-yl)-benzamide,

4-methoxy-N-(7-methoxy-4-morpholin-4-yl-thiazolo[5,4-c]pyridin-2-yl)-benzamide,

3-fluoro-N-(7-methoxy-4-morpholin-4-yl-thiazolo[5,4-c]pyridin-2-yl)-benzamide,

3-methoxy-N-(7-methoxy-4-morpholin-4-yl-thiazolo[5,4-c]pyridin-2-yl)-benzamide,

3-methoxy-N-(7-methoxy-4-morpholin-4-yl-thiazolo[5,4-c]pyridin-2-yl)-4-methylbenzamide, and

N-(7-methoxy-4-morpholin-4-yl-thiazolo[5,4-c]pyridin-2-yl)-3-morpholin-4-yl-benzamide.

4. The compound of formula I in accordance with claim 1 , wherein R 1 is phenyl and R 2 is selected from phenyl, phenyl substituted by halogen and phenyl substituted by lower alkoxy.

5. The compound of formula I in accordance with claim 4 , wherein the compound is selected from

N-(7-methoxy-4-phenyl-thiazolo[5,4-c]pyridin-2-yl)-benzamide,

4-fluoro-N-(7-methoxy-4-phenyl-thiazolo[5,4-c]pyridin-2-yl)-benzamide, and

3-methoxy-N-(7-methoxy-4-phenyl-thiazolo[5,4-c]pyridin-2-yl)-benzamide.

6. The compound of formula I in accordance with claim 1 , wherein R 1 is morpholinyl, R 2 is —(CH 2 ) n -cycloalkyl, and n is 0 or 1.

7. The compound of formula I in accordance with claim 6 , wherein the compound is selected from

2-cyclohexyl-N-(7-methoxy-4-morpholin-4-yl-thiazolo[5,4-c]pyridin-2-yl)-acetamide, and

cyclohexanecarboxylic acid (7-methoxy-4-morpholin-4-yl-thiazolo[5,4-c]pyridin-2-yl)amide.

8. The compound of formula I in accordance with claim 1 , wherein R 1 is morpholinyl and R 2 is selected from pyridyl, and pyridyl substituted by one or more substituents selected from the group consisting of —(CH 2 ) n -heterocyclyl, —(CH 2 ) n -heterocyclyl substituted by hydroxy, and —(CH 2 ) n -heterocyclyl substituted by lower alkoxy.

9. The compound of formula I in accordance with claim 8 , wherein the compound is selected from

2-(3-hydroxy-azetidin-1-yl)-N-(7-methoxy-4-morpholin-4-yl-thiazolo[5,4-c]pyridin-2-yl)-isonicotinamide,

2-(3-methoxy-azetidin-1-yl)-N-(7-methoxy-4-morpholin-4-yl-thiazolo[5,4-c]pyridin-2-yl)-isonicotinamide, and

N-(7-methoxy-4-morpholin-4-yl-thiazolo[5,4-c]pyridin-2-yl)-2-morpholin-4-yl-isonicotinamide.

10. The compound of formula I in accordance with claim 1 , wherein R 1 is selected from phenyl and R 2 is pyridyl, and pyridyl substituted by one or more substituents selected from morpholinyl and lower alkyl.

11. The compound of formula I in accordance with claim 10 , wherein the compound is selected from

N-(7-methoxy-4-phenyl-thiazolo[5,4-c]pyridin-2-yl)-2-morpholin-4-yl-isonicotinamide and

N-(7-methoxy-4-phenyl-thiazolo[5,4-c]pyridin-2-yl)-2-methyl-isonicotinamide.

12. The compound of formula I in accordance with claim 1 , wherein R 1 is morpholinyl and R 2 is selected from benzo [1,3]dioxole, and 2-oxa-5-aza-bicyclo [2.2.1]heptane.

13. The compound of formula I in accordance with claim 12 , wherein the compound is selected from

benzo[1,3]dioxole-5-carboxylic acid (7-methoxy-4-morpholin-4-yl-thiazolo[5,4-c]pyridin-2-yl)-amide, and

(1S,4S)-2-oxa-5-aza-bicyclo [2.2.1]heptane-5-carboxylic acid (7-methoxy-4-morpholin-4-yl-thiazolo[5,4-c]pyridin-2-yl)-amide.

14. A process for preparing a compound of formula I

which process comprises reacting a compound of formula

with a compound of formula

ClC(O)R 2 /base  (20)

wherein,

R 1 is selected from morpholin-4-yl, phenyl and tetrahydropyran-4-yl;

R 2 is selected from

—(CH 2 ) n -aryl;

—(CH 2 ) n -aryl substituted by one or more substituents selected from the group consisting of halogen, lower alkoxy, lower alkyl, —(CH 2 ) n NR′R″, —O(CH 2 ) n —O-lower alkyl, and —(CH 2 ) n -heterocyclyl;

heteroaryl;

heteroaryl substituted by one or more substituents, selected from the group consisting of lower alkyl, lower alkoxy, —(CH 2 ) n NR′R″, —(CH 2 ) n -heterocyclyl, and —(CH 2 ) n -heterocyclyl substituted by one or more substituents selected from hydroxy, lower alkoxy, —(CH 2 ) n —OH, —(CH 2 ) n —O-lower alkyl and lower alkyl;

(CH 2 ) n -cycloalkyl;

—(CH 2 ) n —O-lower alkyl;

NR′R″;

benzo[1,3]dioxole;

2-methyl-1-oxo-2,8-diaza-spiro [4,5] decane;

2-oxa-5-aza-bicyclo[2.2.1]heptane; or

1-oxa-8-aza-spiro[4.5]decane;

R′ and R″ are independently from each other selected from lower alkyl, —(CH 2 ) n —O-lower alkyl, cycloalkyl, and cycloalkyl substituted by hydroxy; and

n is 0, 1 or 2.

15. The process of claim 14 , which further comprises converting the compound obtained into a pharmaceutically acceptable salt thereof.

16. A pharmaceutical composition which comprises a compound of formula I

wherein,

R 1 is selected from morpholin-4-yl, phenyl and tetrahydropyran-4-yl;

R 2 is selected from

—(CH 2 ) n -aryl;

—(CH 2 ) n -aryl substituted by one or more substituents selected from the group consisting of halogen, lower alkoxy, lower alkyl, —(CH 2 ) n NR′R″, —O(CH 2 ) n —O-lower alkyl, and —(CH 2 ) n -heterocyclyl;

heteroaryl;

heteroaryl substituted by one or more substituents, selected from the group consisting of lower alkyl, lower alkoxy, —(CH 2 ) n NR′R″, —(CH 2 ) n -heterocyclyl, and —(CH 2 ) n -heterocyclyl substituted by one or more substituents selected from hydroxy, lower alkoxy, —(CH 2 ) n —OH, —(CH 2 ) n —O-lower alkyl and lower alkyl;

(CH 2 ) n -cycloalkyl;

—(CH 2 ) n —O-lower alkyl;

NR′R″;

benzo [1,3]dioxole;

2-methyl-1-oxo-2,8-diaza-spiro[4,5]decane;

2-oxa-5-aza-bicyclo [2.2.1]heptane; or

1-oxa-8-aza-spiro[4.5]decane;

R′ and R″ are independently from each other selected from lower alkyl, —(CH 2 ) n —O-lower alkyl, cycloalkyl, and cycloalkyl substituted by hydroxy; and

n is 0, 1 or 2;

or a pharmaceutically acceptable salt thereof;

and a pharmaceutically acceptable excipient.